Rare Diseases Today—April 16, 2026

This week’s Rare diseases update highlights regulatory momentum, clinical data readouts, access partnerships, and genomics initiatives shaping diagnosis and treatment across underserved populations.

In Today’s Newsletter

Dive deeper

🧠 Alexion spotlights rare neurology data at AAN 2026 [1] [US • 10 Apr 2026]

https://www.astrazeneca.com/media-centre/press-releases/2026/alexion-data-2026-aan-annual-meeting-reflects-industry-leading-portfolio-commitment-enhancing-care-across-rare-diseases.html
Context: The company highlighted Phase 3 PREVAIL data for gefurulimab in gMG, a KOMET qualitative sub-study for Koselugo (selumetinib) in adult NF1-PN, and CHAMPION-NMOSD analyses for ravulizumab.
Key point: Alexion (AstraZeneca Rare Disease) said it will present 20 datasets at AAN 2026 across generalized myasthenia gravis, neurofibromatosis type 1 plexiform neurofibromas, and NMOSD.
Implication: May influence prescriber choice and payer reviews pending full data.

🎯 Plus Therapeutics wins orphan status for REYOBIQ in pediatric malignant gliomas [2] [US • 08 Apr 2026]

https://www.manilatimes.net/2026/04/08/tmt-newswire/globenewswire/plus-therapeutics-granted-us-fda-orphan-drug-designation-to-reyobiq-in-pediatric-malignant-gliomas/2316294
Context: The company said the designation was broader than requested and includes pediatric ependymoma; REYOBIQ is also being advanced in other CNS cancer programs.
Key point: Plus Therapeutics said the FDA granted orphan drug designation to REYOBIQ (rhenium Re186 obisbemeda) for pediatric malignant gliomas.
Implication: Signals pipeline investment and modality expansion.

🤖 Jaguar Health links AI to crofelemer rare-disease IF plans [3] [13 Apr 2026]

https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/artificial-intelligence-ai-platforms-could-enhance-jaguar-healths-dev-1156912
Context: The announcement cites real-world data mining, possible support for personalized regimens, and a potential future Breakthrough Therapy designation plan for MVID.
Key point: Jaguar Health said it plans to use AI platforms to support development and anticipated commercialization of crofelemer for intestinal failure programs, including pediatric microvillus inclusion disease.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🌍 Veld and Chiesi expand rare-disease access across Africa [4] [Africa • 13 Apr 2026]

https://www.manilatimes.net/2026/04/13/tmt-newswire/globenewswire/veld-pharmaceuticals-gmbh-announces-collaboration-with-chiesi-farmaceutici-spa-to-expand-access-to-rare-disease-therapies-across-africa/2319070
Context: The program is physician-led, named-patient based, and framed as operating under local regulatory, ethical, and pharmacovigilance requirements.
Key point: Veld Pharmaceuticals and Chiesi announced a managed access program for nine rare-disease therapies across Africa.
Implication: May expand screening, initiation, and follow-up at scale.

🧬 Illumina and D3b launch large pediatric genomics effort [5] [US • 14 Apr 2026]

https://www.prnewswire.com/news-releases/illumina-and-the-center-for-data-driven-discovery-in-biomedicine-bring-genomic-data-and-scalable-software-to-the-fight-against-pediatric-cancer-and-rare-disease-302741288.html
Context: The dataset will be made available through the Gabriella Miller Kids First Data Resource Center, using DRAGEN v4.4 and Illumina Connected Analytics.
Key point: Illumina and the Center for Data-Driven Discovery in Biomedicine said they are analyzing 100,000 whole genomes from pediatric patients to support rare disease and cancer research.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🩺 Travere’s Filspari becomes first approved drug for FSGS [6] [US • 14 Apr 2026]

https://www.biospace.com/fda/traveres-filspari-overcomes-phase-3-fail-to-become-first-drug-for-rare-kidney-disease
Context: The report says Phase 3 DUPLEX did not beat Avapro on kidney function at 108 weeks, but the filing also included proteinuria data from DUPLEX and Phase 2 DUET.
Key point: Travere Therapeutics’ Filspari received FDA approval for focal segmental glomerulosclerosis, making it the first approved treatment for FSGS.
Implication: May influence prescriber choice and payer reviews pending full data.

🧪 Yuhan secures FDA orphan designation for Gaucher candidate YH35995 [7] [US • 13 Apr 2026]

https://www.koreabiomed.com/news/articleViewAmp.html?idxno=31275
Context: YH35995 is described as an oral glucosylceramide synthase inhibitor, and the company said preclinical work suggests brain penetration relevant to type 3 Gaucher disease; a Phase 1 study is underway in healthy volunteers in Korea.
Key point: Yuhan said the FDA granted orphan drug designation to YH35995 for Gaucher disease.
Implication: Signals pipeline investment and modality expansion.

Why it matters

Alexion’s AAN package keeps rare neurology, especially gMG and NMOSD, in focus ahead of a major medical meeting [1].
Multiple orphan-drug updates, Plus Therapeutics and Yuhan, show continued FDA incentive use in rare oncology and lysosomal disease [2][7].
Access remains a commercial and public-health theme, with Veld and Chiesi using managed access rather than conventional launch infrastructure in Africa [4].
Data infrastructure is becoming part of the rare-disease story, from Jaguar’s AI framing to Illumina and D3b’s large pediatric genome effort [3][5].
Travere’s FSGS approval shows regulators may accept a broader evidence package when unmet need is high and alternatives are limited [6].

📚 View the full Rare Disease archive on our research hub page

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

FAQ

What did Alexion actually announce for AAN 2026?

Alexion said it will present 20 datasets across gMG, NF1-PN, and NMOSD at AAN 2026. The highlighted programs are gefurulimab in PREVAIL, Koselugo in KOMET, and ravulizumab in CHAMPION-NMOSD and registry analyses [1].

Why is REYOBIQ’s orphan designation notable?

Plus Therapeutics said REYOBIQ received FDA orphan drug designation for pediatric malignant gliomas, and that the scope includes pediatric ependymoma. That matters because the company framed it as broader than originally requested [2].

Is Jaguar reporting clinical proof for crofelemer in MVID here?

Not as a full readout. Jaguar is mainly describing how AI platforms could support development and commercialization, while referencing prior treatment-program observations and a possible Breakthrough Therapy designation plan (details limited to the source) [3].

What is the practical purpose of the Veld–Chiesi program in Africa?

The companies said the managed access program is meant to let physicians, where locally permitted, obtain nine rare-disease therapies on a named-patient basis. It is positioned as an access route for serious unmet need rather than a broad commercial launch [4].

What is unique about the Illumina–D3b collaboration?

The scale. The partners said they are analyzing 100,000 whole genomes from pediatric patients and making insights available through Kids First DRC. The aim is cross-cohort discovery in rare disease and pediatric cancer [5].

How did Filspari win approval after a Phase 3 setback?

According to the report, DUPLEX missed a kidney-function endpoint versus Avapro, but the total package included proteinuria findings from DUPLEX and Phase 2 DUET. The FDA still approved Filspari for FSGS, making it the first approved drug for the indication [6].

Entities / Keywords

Alexion (AstraZeneca Rare Disease), gefurulimab, PREVAIL, Koselugo, selumetinib, KOMET, Ultomiris, ravulizumab, CHAMPION-NMOSD, gMG, NF1-PN, NMOSD
Plus Therapeutics, REYOBIQ, rhenium Re186 obisbemeda, pediatric malignant glioma, pediatric ependymoma, orphan drug designation, FDA
Jaguar Health, crofelemer, intestinal failure, IF, microvillus inclusion disease, MVID, AI platforms, real-world evidence
Veld Pharmaceuticals, Chiesi Farmaceutici, managed access program, MAP, named-patient access, Africa, rare-disease therapies
Illumina, D3b, Center for Data-Driven Discovery in Biomedicine, Kids First DRC, Children’s Brain Tumor Network, DRAGEN, ICA, pediatric genomics
Travere Therapeutics, Filspari, sparsentan, focal segmental glomerulosclerosis, FSGS, DUPLEX, DUET, FDA
Yuhan, YH35995, Gaucher disease, type 3 Gaucher disease, glucosylceramide synthase inhibitor, substrate reduction therapy, orphan drug designation